HYDERABAD, India – India's drug regulator is working to launch this month a new unit that would facilitate access to regulatory information and, hopefully, shore up the willingness of Indian drug companies to take more risks.
HYDERABAD, India – Companies are increasingly willing to invest in biosimilar development and manufacturing in India, despite a spate of regulatory hurdles and a shortage of capital that remain visible.
HYDERABAD, India – Indian pharmaceutical companies are taking baby steps toward a greater collaboration with digital tech firms and data analytics, but they may not be moving fast enough. Delegates at the BioAsia 2018 conference said such collaborations should speed up to tap into that significant innovation potential.
HYDERABAD, India – Companies are increasingly willing to invest in biosimilar development and manufacturing in India, despite a spate of regulatory hurdles and a shortage of capital that remain visible.
HYDERABAD, India – Indian pharmaceutical companies are taking baby steps toward a greater collaboration with digital tech firms and data analytics, but they may not be moving fast enough. Delegates at the BioAsia 2018 conference said such collaborations should speed up to tap into that significant innovation potential.
NEW DELHI – India is looking to reap the benefits of the current global momentum for regenerative medicine, with an anticipated spike in regenerative medicine products in the coming five to eight years, due mainly to the country's bright innovation landscape, both in biotech startups and research institutes.
NEW DELHI – India is looking to reap the benefits of the current global momentum for regenerative medicine, with an anticipated spike in regenerative medicine products in the coming five to eight years, due mainly to the country's bright innovation landscape, both in biotech startups and research institutes.
NEW DELHI – The World Health Organization (WHO) has pre-qualified Indian company Bharat Biotech International Ltd.'s Typbar TCV, its conjugate vaccine against typhoid fever. The pre-qualification paves the way for possible use in childhood immunization programs against typhoid in high-risk, endemic countries.
